Ghent University Hospital
🇧🇪Belgium
Osivax Completes Phase 2a Booster Trial for Broad-Spectrum Influenza Vaccine OVX836
Osivax announced completion of patient visits in its Phase 2a booster trial evaluating OVX836, a broad-spectrum influenza A vaccine candidate targeting the highly conserved nucleoprotein antigen.